PASADENA, Calif., Oct. 16, 2012 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE) is pleased to announce its renowned panel of thought leaders at the prestigious annual Galien Forum being held today at the Alexandria Center for Life Science – New York City. In association with the Galien Foundation, an international organization that recognizes and rewards excellence in scientific innovation, Alexandria will bring together a highly distinguished panel to focus on the topic of Infectious Diseases and discuss future strategies to treat, diagnose and prevent HIV/AIDS, Tuberculosis, Malaria and other important diseases. Joel S. Marcus, Alexandria's Chairman, Chief Executive Officer, and Founder, will provide opening remarks at the Galien Forum and will recognize National Institutes of Health Director Francis S. Collins, MD, PhD, as the 2012 Pro Bono Humanum Honoree at the Galien Awards Ceremony.
Alexandria's esteemed panel will include:
- Moderator: Maria Freire , PhD, President, The Albert and Mary Lasker Foundation
- Panelists: Margaret Hamburg, MD, Commissioner of Food and Drugs, U.S. Food and Drug Administration (FDA) Alice Dautry, PhD, President, Institut Pasteur Julie L. Gerberding, MD, MPH, President, Merck Vaccines, Merck & Co., Inc.; Former Director, Centers for Disease Control and Prevention (CDC) Lynn Marks, MD, Senior Vice President, Projects, Clinical Platforms & Sciences, GlaxoSmithKline plc
Held annually at the Alexandria Center for Life Science – New York City, the Galien Forum is an elite meeting of international thought leaders from the biopharmaceutical industry, academia, and government to catalyze the development of the next generation of novel, breakthrough discoveries that will save lives, manage disease, and reduce the economic burden of disease on society.
Through the Galien Forum, the Alexandria Summit, and other groundbreaking life science events, Alexandria is committed to creating innovative and collaborative life science communities in its best-in-class cluster locations. By bringing together its diverse and longstanding network from the biopharmaceutical industry, academia, finance, and government, Alexandria supports its world-class client tenants and the global life science industry as they tackle the most critical healthcare challenges and shape future directions in life science research and development.About Alexandria Real Estate Equities, Inc. Alexandria Real Estate Equities, Inc. (NYSE: ARE), a self-administered and self-managed real estate investment trust (REIT), is the largest and leading investment-grade REIT focused principally on owning, operating, redeveloping, developing, and acquiring high-quality, sustainable real estate for the broad and diverse life science industry. Founded in 1994, Alexandria was the first REIT to identify and pursue the laboratory niche and has since had the first-mover advantage in every core life science cluster location including Greater Boston, San Francisco Bay, San Diego, New York City, Seattle, Suburban Washington, D.C., and Research Triangle Park. Alexandria's high-credit client tenants span the life science industry, including renowned academic and medical institutions, multinational pharmaceutical companies, public and private biotechnology entities, U.S. government research agencies, medical device companies, clean technology companies, venture capitalists, and life science product and service companies. As the recognized real estate partner of the life science industry, Alexandria has a superior track record in driving client tenant productivity and innovation through its best-in-class laboratory and office space, collaborative locations adjacent to leading academic and medical institutions, unparalleled life science real estate expertise and services, and longstanding and expansive network in the life science community, which we believe result in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For more information, please visit www.are.com. This press release contains forward-looking statements within the meaning of the federal securities laws. Actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained in our Annual Report on Form 10-K and our other periodic reports filed with the Securities and Exchange Commission.